Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + MN58b|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|MN58b||MN58b inhibits choline kinase alpha (CHKA), resulting in decreased growth and increased apoptosis of tumor cells with high CHKA expression (PMID: 26769123, PMID: 28157707).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic ductal adenocarcinoma||not applicable||Fluorouracil + MN58b||Preclinical||Actionable||In a preclinical study, MN58b and Adrucil (fluorouracil) in combination demonstrated an additive effect on growth inhibition of pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26769123).||26769123|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|